Klineo raises €2m to speed up access to cancer trials

Digital health start-up Klineo SAS (Paris) has raised €2m to improve equity of access to clinical trials. Its AI-based platform connects doctors and patients directly with relevant trials in less than a minute. According to the company, its platform  democratises access to new treatments for patients. The proceeds will enable Klineo to expand its platform to all types of cancer, in a context where the number of patients and clinical trials are experiencing significant growth.
 
Clinical trials can offer a chance to advanced-stage cancer patients to benefit from therapeutic innovations. But only 5% of cancer patients (<5%) take part in clinical trials, whereas a majority of patients (>70%) would be willing to participate if they knew about them.
 
Kineo’s platform  allows to search for trials and make direct contact with centres where clinical trials are open. Currently, the platform lists all clinical trials open in France, and matches the patient’s profile to the inclusion criteria.
 
The funds raised from the BPI France and business angels will enable Klineo to cover all cancers in France by the end of 2024, with the first extension in lung cancer. Threafter, the company plans to expand its platform to other countries in Europe and the US and other pathologies such as rare and neurological diseases In addition, the funds will enable Klineo to expand its team and continue to improve the platform both medically and technologically.
 
Klineo initiated a pilot project at the Gustave Roussy Institute in 2022 and launched the first national platform for triple-negative breast cancer in collaboration with a patient association, the Collectif Triplettes Roses. In 2023, Klineo extended its platform to include breast and skin malignancies as well as lymphoma. It aims to cover all cancers by the end of 2024. Klineo also benefits from the support of a number of players, including the BPI, the Pfizer Healthcare Hub, Wilco, Onconumérique, PariSanté Campus and Unicancer, which awarded Klineo the “Jury’s Favourite” prize as part of the Prix de l’Innovation 2022. Klineo works in partnership with both industrial sponsors  such as Pfizer, AstraZeneca, Pierre Fabre, MSD and academic institutions such as Unicancer, LYSARC, etc..